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ABSTRACT
Osteosarcoma is the second leading cause of cancer-related death for children and young adults. In this study, we have subcutaneously
injected—with and without matrigel—athymic mice (Fox1nu/nu) with human osteosarcoma 3AB-OS pluripotent cancer stem cells (CSCs),
which we previously isolated from human osteosarcoma MG63 cells. Engrafted 3AB-OS cells were highly tumorigenic and matrigel greatly
accelerated both tumor engraftment and growth rate. 3AB-OS CSC xenografts lacked crucial regulators of beta-catenin levels (E-cadherin,
APC, and GSK-3beta), and crucial factors to restrain proliferation, resulting therefore in a strong proliferation potential. During the ﬁrst weeks
of engraftment 3AB-OS-derived tumors expressed high levels of pAKT, beta1-integrin and pFAK, nuclear beta-catenin, c-Myc, cyclin D2,
along with high levels of hyperphosphorylated-inactive pRb and anti-apoptotic proteins such as Bcl-2 and XIAP, and matrigel increased
the expression of proliferative markers. Thereafter 3AB-OS tumor xenografts obtained with matrigel co-injection showed decreased
proliferative potential and AKT levels, and undetectable hyperphosphorylated pRb, whereas beta1-integrin and pFAK levels still increased.
Engrafted tumor cells also showed multilineage commitment with matrigel particularly favoring the mesenchymal lineage. Concomitantly,
many blood vessels and muscle ﬁbers appeared in the tumor mass. Our ﬁndings suggest that matrigel might regulate 3AB-OS cell
behavior providing adequate cues for transducing proliferation and differentiation signals triggered by pAKT, beta1-integrin, and pFAK
and addressed by pRb protein. Our results provide for the ﬁrst time a mouse model that recapitulates in vivo crucial features of
human osteosarcoma CSCs that could be used to test and predict the efﬁcacy in vivo of novel therapeutic treatments. J. Cell. Biochem.
113: 3380–3392, 2012.  2012 Wiley Periodicals, Inc.
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O steosarcoma, the most common of primary bone malignan-cies, is among a group of mesenchymal cancers character-
ized by clinical, histologic and molecular heterogeneity, and
karyotypes with a high degree of aneuploidy [Smida et al., 2010].
It is a highly aggressive tumor with a high metastasizing potential
and, at present, it remains the second leading cause of cancer-related
death for children and young adults [Ta et al., 2009]. The current
standard protocol of a three-drug chemotherapy regimen, using
cisplatin, doxorubicin, and high-dose methotrexate, results in no
more than 70% long-term disease-free survival for osteosarcoma
patients without metastasis [Wesolowski and Budd, 2010]. There is
no established second-line chemotherapy for relapsed osteosarco-
ma, and therefore new therapeutic approaches are urgently needed.
It is well established that most solid tumors are hierarchically
organized and that their growth is sustained by a distinct
subpopulation of cells, termed cancer stem cells (CSCs) [Clevers,
2011], which represent the source for tissue renewal and hold
malignant potential [Li and Neaves, 2006; Maitland and Collins,
2008]. CSCs confer resistance to therapies; thus, a successful cure of
cancer should require CSCs eradication.
We have recently demonstrated that prolonged treatments (about
100 days) of human osteosarcoma MG63 cells with 3-aminobenza-
mide (3-AB), a potent competitive inhibitor of poly(ADP-ribose)-
polymerase (PARP), induce massive cell death followed by
progressive enrichment of a new CSC population named 3AB-OS.
This 3AB-OS CSC line [Di Fiore et al., 2009] has been recently
patented (‘‘Pluripotent cancer stem cells: Their preparation and use’’.
FI2008A000238. 11/12/2008. N. PCT/IB2009/055690, 11/12/2009)
and represents a pluripotent, heterogeneous, and stable cell
population, which has been characterized at the molecular [Di
Fiore et al., 2009] and genetic level [Di Fiore et al., paper submitted].
Overall, our results have suggested that the original human
osteosarcoma MG63 cells might contain a rare population of
multipotent CSCs, which has been selected and enriched by 3AB
treatment.
The translation of therapeutic strategies for osteosarcoma from
the experimental phase into the clinic has been limited by
insufﬁcient animal models bearing the basic features of human
tumors. Generating an appropriate and reliable experimental model
of human cancer is crucial to identify and test possible antitumor
strategies.
Xenograft models obtained through transplantation of cancer cell
lines into immunodeﬁcient mice are very useful to analyze the
molecular mechanisms underlying tumor development and to
identify novel molecular therapeutic approaches. Tumor cell
xenografts can be readily accepted by immunocompromised
mice, such as athymic nude mice bearing a genetic mutation that
causes thymic aplasia and results in an inhibited immune system
[Sharkey and Fogh, 1984]. The athymic nude mouse can receive
many different types of tissue and tumor grafts providing a model
that is easy to manage, easy to establish, and very effective for
testing tumor treatments; it is characterized by a consistent and
reproducible cell growth and permits easy access to the tumor for
treatment, caliper measurement, and imaging evaluation, repre-
senting, therefore, a useful model for studying the biology and
response to therapies of human tumors in vivo. Here, we report a
xenograft model of human osteosarcoma CSCs that could be
clinically relevant. Because of the distinctive capability of CSCs to
recapitulate the development of the original tumors in vivo, human
osteosarcoma 3AB-OS CSC xenografts into nudemice might provide
an avenue for testing in vivo approaches to pathway-targeted drug
discovery and preclinical screening and to investigate the behavior
of human osteosarcoma CSCs.
MATERIALS AND METHODS
CELL LINES AND CULTURE CONDITIONS
The human osteosarcoma MG63 cells were acquired from Interlab
Cell Line Collection (Genova, Italy). The human 3AB-OS CSCs were
generated in our laboratory [Di Fiore et al., 2009]. 3AB-OS and
MG63 cells were cultured as monolayers in Dulbecco’s modiﬁed
Eagle medium (DMEM), supplemented with 10% (v/v) heat
inactivated fetal bovine serum, 2mM L-glutamine, and penicillin–
streptomycin antibiotics (50mg/ml) (Euroclone, Pero, Italy) in a
humidiﬁed atmosphere of 5% CO2 in air at 378C. When cells grew to
approximately 80% conﬂuence, they were subcultured or harvested
using 0.25% trypsin-EDTA (Life Technologies Ltd).
MATRIGEL
BDMatrigelTM, purchased from BD Biosciences- Discovery Labware,
Becton Dickinson, (Buccinasco, Italy), is a solubilized basement
membrane preparation extracted from the Engelbreth-Holm-Swarm
(EHS) mouse sarcoma. It polymerizes under normal physiological
conditions to produce a reconstituted, biologically active matrix,
which favors cell attachment and differentiation. As BD Matrigel
rapidly gels at 22–358C, it was thawed overnight at 48C, aliquoted on
ice into pre-cooled sterile microcentrifuge tubes and then frozen at
208C until use. All procedures involving Matrigel were carried out
at 48C on ice to prevent polymerization.
CELL LINES AND MOUSE XENOGRAFT GENERATION
MG63 and 3AB-OS cells were proven to be free of mycoplasma
infection by reverse-transcriptase polymerase chain reaction
(RTPCR) (Takara Shuzo Co, Ltd, Kyoto, Japan) of supernatant
from densely growing cells. MG63 and 3AB-OS cells to be implanted
were harvested at approximately 80% conﬂuence, washed in
phosphate-buffered saline (PBS) (Life Technologies Ltd), resus-
pended in serum-free culture medium, counted in a hemocytometer,
and equilibrated at a density of 3 106 cells per 150ml DMEM. Cell
viability was assessed through trypan blue staining.
MG63 cells and 3AB-OS cells (3 106) were both prepared in
either DMEM or DMEM/Matrigel (1/1 mixture), into a ﬁnal volume
of 300ml for injection. Cells were injected subcutaneously into
the ﬂank of 4-week old male athymic nude mice. Male athymic
nude mice (Foxn1nu/nu), carrying a disruption of the forkhead box
n1 gene [Coffer and Burgering, 2004], which leads to thymic atrophy
and immunodeﬁciency [Nehls et al., 1996], were purchased from
Harlan, Udine, Italy. Mice were acclimated for 1 week before the start
of this study. All animals have received humane care in compliance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’
published by the National Institutes of Health. The authors have
received prior permission from their Institutional Animal Care&Use
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Committee (IACUC). Dr. Patrizia Di Marco was the accredited
veterinarian.
Fifteen animals were used for each treatment group as reported in
results. Animals were kept in a light- and temperature-controlled
environment and provided with food and water ad libitum.
MOUSE HEALTH AND CONDITION ASSESSMENT
AND TUMOR MEASUREMENT
Mice were inspected for tumor appearance, by daily observation and
palpation. To minimize pain, discomfort, and distress, all mice were
observed daily for their behavior and body weight (BW)—recorded
every week—was used as an index of mice-welfare. BCS, which
ranges from 1 (emaciation) to 5 (obesity), was determined by
visual and hands-on examination of each animal. The hands-on
examination was done by holding the mouse by the base of the tail
and passing a ﬁnger over the sacroiliac bones and vertebral column
[Ullman-Cullere´ and Foltz, 1999]. We established that BCS had not
to exceed 2, with BCS¼ 2 corresponding to ‘‘underconditioned’’
(with segmentation of vertebrae and dorsal pelvic bones readily
palpable), and the mean tumor size had not to exceed 10% of the
mouse BW. Tumor volume was calculated through an external
caliper, measuring twice weekly the greatest longitudinal diameter
(length) and the greatest transverse diameter (width) and volumes
were calculated by the formula ‘‘Tumor volume (mm3)¼width2
length 0.52 [Euhus et al., 1986; Tomayko and Reynolds, 1989].
Mice were sacriﬁced by cervical dislocation and tumor samples and
tissues were collected at 3, 5, and 7 weeks after cell injection.
TUMOR AND TISSUE HISTOLOGY, HISTOCHEMICAL, AND
IMMUNOHISTOCHEMICAL STAINING
Tumors and tissues (hearts, lungs, kidneys, spleens, livers, and
brains) were processed for macroscopic and histological examina-
tion. For light microscopy examination, tumors and tissues were
ﬁxed with 10% phosphate-buffered formalin and embedded in
parafﬁn. Sections (4mm thick) were cut and stored at room
temperature until use. Routine histology (hematoxylin–eosin
staining, H&E) was performed in order to evaluate basic
histomorphological features of the specimens. The avidin-biotin-
peroxidase complex (LSAB, Dako Corp., Santa Barbara, CA) method
was used for immunohistochemical analyses. Tissue sections were
sequentially dewaxed through a series of xylene, graded alcohol,
and water immersion steps. Antigen was retrieved in citrate buffer
(pH 6.0) microwave digestion (2 cycles of 5min each, 750W).
Endogenous peroxide activity was suppressed by incubating the
sections with 0.3% hydrogen peroxidase in methanol for 30min at
room temperature. After three 10-min rinses in PBS, all tissue
sections were incubated with 1% bovine serum albumin for 30min
at room temperature. Primary antibodies used in this study and
their speciﬁc dilutions are summarized in Supplementary Table 1.
Primary antibodies were diluted in PBS with 10.1% normal albumin
serum and were incubated overnight at 48C. After incubation, the
slides were rinsed three times with PBS for 5min, and incubated for
30min at room temperature with the speciﬁc biotinylated secondary
anti-rabbit, anti-goat, or anti-mouse antibody (LSAB, Dako Corp.,
Santa Barbara, CA). After two 5-min rinses with PBS, tissue
sections were incubated in PBS for 1 h at room temperature with
streptavidin, horseradish peroxidase conjugate. All tissue sections
were rinsed three times with Tris-buffer saline (TBS), incubated with
the chromogen 3-30-diaminobenzidine tetrahydrochloride (DAB;
Dako) diluted 0.035% in TBS for 1min, rinsed in tap water, and
counterstained with Mayer’s hematoxylin. The speciﬁc primary
antibodies were replaced by PBS or normal goat serum in tissue
sections used as negative controls.
Criteria to indicate marker expression in this study were as
follows: The number of positive cells was semiquantitatively
evaluated by counting the number of stained cells in 8–10 randomly
chosen ﬁelds, counting at least 1,000 cells, at high magniﬁcation
(40 objective and 10 eyepiece); four degrees of positivity for
PCNA and Ki-67 were identiﬁed: ‘‘ ’’ (0–24%), ‘‘þ ’’ (25–50%),
‘‘þþ’’ (51–74%), ‘‘þþþ’’ (75–100%); four degrees for other
markers were identiﬁed: ‘‘ ’’ no positive cell, ‘‘þ ’’30%, ‘‘þþ’’
31–70%, and ‘‘þþþ’’ 71%.
Images of stained tissues were captured using Leica DMR
microscope equipped with a Leica DFC 320 digital camera. The
images were visualized with epiﬂuorescent ﬁlters and transferred to
Adobe Photoshop CS4 (Adobe Systems, San Jose, CA).
MITOSIS COUNT
Mitoses were counted in ﬁve ﬁelds (40 lens) on replicate sections
stained with toluidine blue which enhances the detection of mitotic
ﬁgures.
RNA EXTRACTION AND REAL-TIME QUANTITATIVE RT-PCR
RNA was extracted from four 20mm formalin-ﬁxed parafﬁn-
embedded (FFPE) sections for each sample. Parafﬁn was removed by
xylene extraction followed by ethanol wash. RNA was isolated from
sectioned tissue blocks using the RecoverAllTM Total Nucleic Acid
Isolation Kit (Ambion, Life Technologies Corporation); a DNase I
treatment step was included. One microgram of total RNA was
reverse transcribed in a ﬁnal volume of 20ml Reverse transcription
(RT) by using a Super-Script First-Strand Synthesis kit for RT-PCR
(Invitrogen), according to the manufacturer’s instructions. The
resulting cDNAs were used for Quantitative real-time PCR (qPCR)
using the primers (Proligo, Milan, Italy) reported in Supplementary
Table 2 and the Power SYBR1 Green PCR Master Mix (Applied
Biosystem, Warrington, UK). Reactions were performed in 48-well
plates according to manufacturer’s instructions, using Applied
Biosystems StepOneTM instrument. Each reaction mixture contained
2ml of template cDNA, 12.5ml of SYBR Green PCRMaster Mix 2, a
ﬁnal concentration of 300 nM of forward and reverse primers and
RNase-free dH2O to a ﬁnal volume of 25ml. qPCRs were performed
in triplicate and repeated for conﬁrmation. PCR cycling was
performed as follows: 958C for 10min; 958C for 30 s, 608C for 60 s,
and 728C for 30 s for 40 cycles; and a ﬁnal extension at 728C for
5min. To determine primer speciﬁcity, three stages (958C for 15 s,
608C for 20 s, and 958C for 15 s, with a ramping time of 20min) were
added at the end of the PCR to obtain dissociation curves for each
gene. To verify that the RT-PCR signals derived from RNA rather
than genomic DNA, for each gene tested a control identical to the
test assay but omitting the RT reaction (no RT control) was included.
qPCR data were analyzed by SDS 2.1 software. Relative transcript
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levels were determined using the 2-DDCt method and normalized to
endogenous b-actin control.
STATISTICAL ANALYSIS
Data were expressed as mean SE. Results of in vivo tumorigenicity
assays and real-time RT-PCR analyses were evaluated by Student’s
t-test. Differences were considered signiﬁcant when P< 0.05.
RESULTS
EVALUATION OF IN VIVO TUMORIGENICITY OF MG63 CELLS
AND 3AB-OS CSCS
We have previously shown [Di Fiore et al., 2009] that 3AB-OS
osteosarcoma cells possess in vitro the most signiﬁcant properties
of CSCs, including the ability to initiate tumors. Here, we have
examined in vivo, in xenografted nude mice, the tumor-initiating
capacity of both human osteosarcoma 3AB-OS CSCs and parental
human osteosarcoma MG63 cells. To examine the tumorigenic
potential of both cell lines (MG63 and 3AB-OS) 3 106 cells were
mixed with either matrigel or cell culture medium and injected
subcutaneously into 4 week-old immunocompromised mice. As
reported in Table I, mice were subdivided into six groups, each
composed of 15mice. Each group was then further divided into three
subgroups corresponding to the times when mice were sacriﬁced,
i.e., at the end of the 3rd, 5th, and 7th week following inoculation
(mice were 7, 9, and 11 week-old, respectively), if allowed by health
conditions and ethical reasons. Control animals were either un-
inoculated or inoculated with matrigel. Figure 1A is a representative
picture of animals of each group subcutaneously inoculated with
cancer cells. As shown in both Table I and Figure 1A, none of the
mice inoculated with matrigel alone (0/15) or with MG63 cells alone
(0/15) developed tumors. Even if some mice (4/15) co-inoculated
with MG63 cells and matrigel developed a modest subcutaneous
reaction (Fig. 1A), by histology it appeared to be composed of
soft fatty tissue only (not shown). Instead, when mice were
inoculated with 3AB-OS cells alone, tumors developed in 75% of
mice (11/15 mice), or in 100% of mice (15/15 mice) when cells were
injected in the presence of matrigel.
TABLE I. Evaluation of In Vivo Tumorigenicity of MG63 and 3AB-OS Cells
Inoculation
Tumors/
mice
Tumor volume
(mm3)/3 weeks
Tumor weight
(gr)/3 weeks
Tumor volume
(mm3)/5 weeks
Tumor weight
(gr)/5 weeks
Tumor volume
(mm3)/7 weeks
Tumor weight
(gr)/7 weeks
— 0/15 — — — — — —
Matrigel 0/15 — — — — — —
MG63 cells 0/15 — — — — — —
MG63 cellsþmatrigel 0/15 — — — — — —
3AB-OS cells 11/15 117 0.1 1,400 1.197 3,420 2.923
3AB-OS cellsþmatrigel 15/15 1,520 1.29 3,610 3.080 — —
P< 0.05.
Fig. 1. Evaluation of in vivo tumorigenicity of MG63 cells and 3AB-OS CSCs. A: Xenograft formation in Fox1nu/nu mice. Representative images of mice sc-injected with
either MG63 or 3AB-OS cells in the absence or presence of matrigel. B: Comparison of xenograft formation in vivo. Tumor volumes were measured and calculated each week.
Tumor growth was plotted against time. Results are reported as mean SD. P-values were calculated with Student’s t-test. Values of P< 0.05 were considered statistically
signiﬁcant.
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However, tumor volume strongly depended on both the presence
of matrigel and the engraftment time. More precisely, mice co-
inoculated with 3AB-OS cells and matrigel, developed tumors,
which were, at 3 and 5 weeks of engraftment, about 13 and 2.6-times
greater than those found in mice inoculated with 3AB-OS cells
alone. (Table I and Fig. 1A and B). As shown in Figure 1B, the trend
of tumor growth over time in mice co-inoculated with 3AB-OS cells,
with or without matrigel, was similar, although matrigel seemed to
greatly accelerate both tumor engraftment and growth rate.
Consistently, mice inoculated with 3AB-OS cells alone reached
the endpoint (tumor weight had overcome 10% of the BW and
mice were sacriﬁced for ethical reasons) at the 7th week after
engraftment, whereas mice engrafted with the same cells in presence
of matrigel were sacriﬁced at the 5th week.
Overall, Table I and Figure 1 show that, while MG63 cells do not
possess tumor-forming ability in vivo, 3AB-OS cells are highly
tumorigenic and matrigel greatly accelerated both tumor engraft-
ment and growth rate. These results permitted to establish that the
3rd and 5th week of tumor engraftment in the presence of matrigel
may be compared to the 5th and 7th week of tumor engraftment in
the absence of matrigel. This statement was followed to describe the
results reported in the successive paragraphs.
None of the engrafted mice ever developed clinical symptoms
suggesting pathogenic human tumor cell dissemination in host
tissues. To analyze whether tumor cells engraftment produced
metastasis, internal organs of mice (heart, lungs, kidneys, spleen,
liver, and brain) were removed, for macroscopic and microscopic
analyses, following sacriﬁce. In our experiments, all inoculated mice
remained healthy during the whole period of treatment and
metastases were not observed in any of the studied animals.
Figure 2 is a representative picture of mouse host tissues, analyzed
both macroscopically (Fig. 2A) and microscopically after staining of
FFPE sections with H&E (Fig. 2B), which shows the absence of any
gross histological evidence of damage or cancer cell inﬁltration.
HISTOLOGY AND PROLIFERATIVE POTENTIAL OF TUMORS DERIVED
FROM SUBCUTANEOUSLY INOCULATED 3AB-OS CSCS
First, to conﬁrm that tumors derived from 3AB-OS cells engraftment
were composed of human cells, tumor sections were stained with
anti-human nuclear antigen monoclonal antibody. In addition, as a
control for the speciﬁcity of the antibody against human antigens
we used a section of mouse liver tissue. As shown in Figure 3A, the
tumor section showed a strong reaction with the anti-human nuclear
Fig. 2. Macroscopic and histological examination of internal organs of mice injected with either 3AB-OS or MG63 cells. A: Morphology of the internal organs (heart, lungs,
kidneys, spleen, liver, and brain) removed from xenografted host mice. B: H&E staining of various host tissues (Original magniﬁcation, 25).
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antigen antibody whereas no cross-reactivity was observed in the
mouse liver section.
The analysis of 3AB-OS cell-derived tumor grafts has shown
some common features that were evidenced in all experimental
conditions (with or without matrigel; engraftment at 3, 5, or 7
weeks). Figure 3B–E, which includes representative pictures of the
tumor microscopy, shows the gross microscopic appearance of the
tumors that were circumscribed by a macroscopic ﬁbrous capsule
and pericapsular ﬁbrosis, which was not involved in cell
proliferation (Fig. 3B), and that became thinner during tumor
growth (not shown). The tumors appeared well vascularized with
several blood vessels passing through; cells contained large
vesicular and empty-looking nuclei and a thick, distinct nuclear
membrane, with coarse chromatin dispersion; the cytoplasm was
Fig. 3. Histology and proliferative potential of tumors derived from subcutaneously inoculated 3AB-OS CSCs. A: Staining of a tumor section with an anti-human antibody to
establish the human origin of tumor cells. A liver mouse section was used as a negative control. B, C: Topography of a typical 3AB-OS-derived xenograft nodule after staining
with H&E (Original magniﬁcation, 25 and 200, respectively). D: Mitotic ﬁgures of Toluidine-stained FFPE tumor sections (Original magniﬁcation, 400). E: Histological
analyses of tumors derived from mice injected with 3AB-OS cells either with or without matrigel at 3, 5, and 7 weeks of engraftment (H&E, Original magniﬁcation 200).
F: Tumor sections immunostained for PCNA (proliferating cell nuclear antigen) and Ki-67, two of the most frequently used cell proliferation markers. Comparison between
the ﬁfth week of 3AB-OS engraftment with matrigel and the 7th week 3AB-OS engraftment in its absence. G: Real-Time PCR analysis of MKI67. mRNA levels were normalized
by b-actin. Data were expressed as mean SE. P-values were calculated using Student’s t-test. Differences were considered signiﬁcant at P< 0.01.
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usually abundant and ﬁnely granular, basophilic, with no distinct
cell border (Fig. 3C). Cells, which often appeared multinucleated,
showed marked anaplasia—including abnormal forms—numerous
mitotic ﬁgures (>6 to 40), aberrant mitosis (Fig. 3D). However,
tumors also showed some signiﬁcant histologic differences which
depended on the time of tumor development and the presence/
absence of matrigel. Indeed (Fig. 3E), in the absence of matrigel, at
5 weeks after engraftment, tumors consisted of densely packed cells,
sometimes with spindle-like shape, more frequently polygonal,
mostly undifferentiated, without morphological organization, and
with some blood vessels being visible. After 7 weeks, neoplastic cells
showed crowding and overlapping, generated different patterns of
organization, including bundles and vortexes, and a greater number
of blood vessels crossed the tumor. When the tumors developed in
the presence of matrigel, at 3 weeks after engraftment the cells
appeared more densely packed than in the absence of matrigel,
and polygonal and fusiform cells were much more numerous and
organized into bundles that showed strong aspects of differentiation
for the presence of muscle ﬁbers. Cells in a rosette-like arrangement
were also visible. After 5 weeks (which was the ﬁnal endpoint
for cells injected with matrigel, as reported in Fig. 1) aspects of
differentiation were more numerous, a much greater number of
blood vessels and multinucleated cells were present, and a larger
number of muscle ﬁbers crossed the tumor. Therefore, as matrigel
seemed to provide a more favorable environment for tumor
engrafment, cell growth and differentiation, we also assessed
the proliferative state of the cells. To this purpose, tumor sections
were immunostained for proliferating cell nuclear antigen (PCNA)
and Ki-67, two of the most frequently used cell proliferation
markers, which recognize nuclear antigens associated with all the
phases of the cell-cycle except G0, with their maximal expression
level during the S phase, nearby before the beginning of DNA
synthesis [Muskhelishvili et al., 2003]. Comparing the 3rd week of
tumor cell engraftment with matrigel with the 5th week of tumor cell
engraftment in its absence, we observed a very high index of cell
proliferation (with both PCNA and Ki-67 labelling indexes) with a
few differences between the two conditions (Table II). Thereafter, cell
proliferation index decreased and its level was much lower in tumor
cells engrafted in the presence of matrigel (5th week) than in its
absence (7th week, Fig. 3F and Table II).
Similar results were obtained also by comparing, through Real
Time RT-PCR, mRNA extracted from FFPE tumors derived from
engraftment in the presence and absence of matrigel. Indeed, the
presence of matrigel decreased (1.4-fold) the mRNA levels of
MKI67, encoding the antigen identiﬁed by the Ki-67 monoclonal
antibody (Fig. 3G).
Overall, these data suggest that matrigel, interacting with
endogenous microenvironment might provide adequate cues to
reduce cell proliferation.
CELL LINEAGE AND DIFFERENTIATION STATE OF TUMORS DERIVED
FROM 3AB-OS CSCS ENGRAFTMENT
Cultured 3AB-OS cells possess pluripotent stem cell potential, as
they are capable of giving rise—under speciﬁc inductive condi-
tions—to cell derivatives of the three germ layers (ecto, endo, and
mesoderm) [Vento et al., manuscript in preparation]. To evaluate
whether 3AB-OS cells preserve in vivo these features of the cultured
3AB-OS cells, we assessed cell lineage and differentiation potential
of engrafted 3AB-OS tumor cells (with and without matrigel), by
immunohistochemical staining for GFAP (an ectodermal marker),
vimentin (a mesodermal marker), and alfa-fetoprotein (an endoder-
mal marker). As shown in both Figure 4 and Table III, at the 3rd week
of 3AB-OS cell engraftment in the presence of matrigel, the
percentage of tumor cell positivity for the three markers was
markedly higher (71, 97, and 61% for GFAP, vimentin, and AFP,
respectively) than in tumor cells at the 5th week of engraftment
without matrigel (40, 13, and 30% for GFAP, vimentin, and AFP,
respectively).
At the 5th week of engraftment in the presence of matrigel,
the strong positive levels of the three markers were maintained,
whereas in the corresponding samples (at the 7th week of
engraftment without matrigel) positivity for the three markers
markedly increased (64, 50, and 33%, respectively) thus that, at
these engraftment times, a minor difference between the marker
levels measured in the presence or absence of matrigel was
observed.
Overall, these results suggest that engrafted 3AB-OS CSCs retain
their differentiation potential. However, matrigel seems to induce
a strong commitment to differentiation along the mesenchymal
lineage, consistent with an increased morphological differentiation
into muscle ﬁbers, which is probably triggered by matrigel
cooperation with the subcutaneous microenvironment.
EVALUATION OF MARKERS REQUIRED FOR STEM CELLS STATE
Our previous results [Di Fiore et al., 2009; Di Fiore et al., paper
submitted] have shown that 3AB-OS cells express at high levels most
crucial stemness markers (CD133, Oct3/4, hTERT, nucleostemin,
Nanog, ABCG2, Lin28B, SOX2, Nestin, and HMGA2) known to be
involved in the maintenance of the stem cell status. Here, we
measured pluripotency and immortality markers by evaluating
immunoreactivity of tumor cells, engrafted with and without
TABLE II. Evaluation of Cell Proliferation Index During Tumor Growth
Cell Pro
markers
 Matrigel þ Matrigel
5 weeks (positivity) 7 weeks (positivity) 3 weeks (positivity) 5 weeks (positivity)
% Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees
PCNA 89.8 4.3 þþþ 73.8 2.7 þþ 98.8 1.1 þþþ 42 3.9 þ
Ki-67 65.5 3.1 þþ 53.2 4.1 þþ 51 2.2 þþ 31.1 4.2 þ
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matrigel, versus the above reported genes. The results showed that,
at the 3rd week of engraftment with matrigel no signiﬁcant
differences were found compared with the 5th week of engraftment
without matrigel (not shown), whereas at the 5th week of
engraftment with matrigel, tumors were much less immunoreactive
than at the 7th week of engraftment without matrigel (Fig. 5A and
Table IV). More precisely, as reported in the table, comparing the
5th week with matrigel to the 7th week without matrigel, the results
show that in the presence of matrigel CD133 immunoreactivity
decreased by 37.9%; Lin28B, ABCG2, SOX2, Nanog, and HMGA2,
showed a decrease that ranged from 26 to 22%; Nucleostemin (NS),
h-TERT, Nestin, and Oct3/4 showed a decrease that ranged from
20 to 17%. Comparing mRNA extracted from FFPE tumors,
engrafted with and without matrigel, Real Time RT-PCR assays
have shown (Fig. 5B) that in the presence of matrigel, mRNA
levels of OCT4, Nanog, and CD133 were signiﬁcantly lower than
in its absence. Overall, these data suggest that matrigel might have
provided the environmental cues for a gradual loss of stemness.
POTENTIAL SIGNALING PATHWAYS INVOLVED IN 3AB-OS
CSCS TUMORIGENICITY
Unscheduled cell division is a characteristic of cancer cells. We have
previously shown [Di Fiore et al., 2009] that 3AB-OS cells express
higher levels of cell cycle checkpoint proteins (hyperphosphory-
lated/inactive pRb E2F1, cyclin D1, E, A, and B1, and cdc2) than
parental MG63 cells. 3AB-OS cells also showed a much higher level
of nuclear beta-catenin—known to control cyclin D1 expression—
and express a greater number of proteins with anti-apoptotic
activity (FlipL, Bcl-2, XIAP, IAP1, IAP2, and survivin).
Figure 6A and Table V—which describe immunohistochemical
analyses of tumor cells at the 3rd week of engraftment in the
presence of matrigel, show that tumor cells were strongly positive
for the hyperphosphorylated/inactive pRb form (73%), cyclin D2
(85%), and c-Myc (74%). Similar results were obtained at the
5th week of engraftment without matrigel (Table V). These results
indicated a potent activation of cell-cycle transitions, i.e., G1/S and
G2/M, and suggested that signaling pathways involved in cell
Fig. 4. Cell lineage and differentiation state of tumors derived from 3AB-OS CSC engraftment. Tumors at 3, 5, and 7 weeks of engraftment with or without matrigel.
Immunohistochemical analyses of GFAP, vimentin, and a-fetoprotein expression. (Original magniﬁcation, 400).
TABLE III. Evaluation of Lineage-Related Markers During Tumor Growth
Lineage
markers
 Matrigel þ Matrigel
5 weeks (positivity) 7 weeks (positivity) 3 weeks (positivity) 5 weeks (positivity)
% Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees
GFAP 40.2 4.1 þþ 64.1 3.1 þþ 70.7 2.6 þþ 69.8 3.9 þþ
VIM 12.8 3.7 þ 50.4 1.4 þþ 96.6 2.5 þþþ 95.4 4.2 þþþ
AFP 30.6 5.3 þ 32.6 1.7 þþ 60.6 3.3 þþ 57.9 4.5 þþ
JOURNAL OF CELLULAR BIOCHEMISTRY 3AB-OS HUMAN OSTEOSARCOMA CSCS XENOGRAFT 3387
Fig. 5. Evaluation of markers required for Stem Cells State. A: Immunohostochemical analysis of CD133, nucleostemin (NS), Lin28B, Nanog, Oct3/4, ABCG2, HMGA2, SOX2,
Nestin, and hTERT expression. (Original magniﬁcation, 400). B: Oct4, Nanog, and CD133 mRNA levels were determined by real-time PCR analysis and normalized by b-actin.
Data were expressed as mean SE. P-values were calculated using Student’s t-test. Differences were considered signiﬁcant at P< 0.01.
TABLE IV. Evaluation of Stem Cell-Related Markers During Tumor Growth
Stem cells markers
 Matrigel þ Matrigel
7 weeks 5 weeks
% of positivity mean S.D. Degrees of positivity % of positivity mean S.D. Degrees of positivity
CD133 98.3 1.3 þþþ 61 3.8 þþ
Lin28B 74.8 3.6 þþþ 55.8 4.7 þþ
ABCG2 98.4 1.4 þþþ 72.1 2.8 þþþ
SOX2 72 0.8 þþþ 55 2.6 þþ
Nanog 74.4 4.3 þþþ 56.4 3.3 þþ
HMGA2 80 4.1 þþþ 62.5 1.3 þþ
Nucleostemin (NS) 97.3 2.5 þþþ 77.3 5.5 þþþ
hTERT 64.9 3.4 þþ 52.1 0.4 þþ
Nestin 93.4 2.8 þþþ 77.6 4.8 þþþ
Oct3/4 91.3 5.2 þþþ 75.2 3.2 þþþ
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survival, proliferation, and invasiveness might be preferentially
activated in engrafted 3AB-OS cells. Analyses of Wnt and AKT
signaling performed at the same weeks of engraftment described
above showed that the cells were negative for GSK-3b, APC, and
E-cadherin, suggesting that the canonical WNT signal is disrupted.
Instead, cells were highly positive for b1-integrin (61%), pAKT
(97%), pFAK (77%), and b-catenin (70%), with these three latter
markedly accumulating in the nucleus. Moreover, cells were
strongly positive for BCL-2 (96%) and XIAP (98%), thus evidencing
the presence of potent antiapoptotic signals (Fig. 6A). Only a few
differences were found comparing tumors engrafted at the 3rd and
5th week with and without matrigel (not shown). Conversely, by
comparing the 5th week of engraftment with matrigel to the 7th
week of engraftment without matrigel (Fig. 6B and Table V),
immunohistochemical analyses showed that tumor cells were much
less immunoreactive versus cyclin D2, c-Myc, and b-catenin in the
Fig. 6. Potential signaling pathways involved in 3AB-OS CSCs tumorigenicity. A: Tumors at 3 weeks of engraftment with matrigel. Immunohistochemical analyses of
pRb (Ser 795), cyclin D2, c-Myc, GSK-3b, E-cadherin, APC, pAKT (Ser 473), b1-integrin, pFAK (Tyr 397), b-catenin, Bcl-2, and XIAP expression. (Original magniﬁcation,
400). B: Tumors at 5, and 7 weeks of engraftment with or without matrigel. Immunohistochemical analyses of cyclin D2, c-Myc, b-catenin, Bcl-2, XIAP, pAKT
(Ser 473), b1-integrin, pFAK (Tyr 397), pRb (Ser 795), and pRb expression. (Original magniﬁcation, 400). C: Real-Time PCR analysis of b-catenin c-Myc, Bcl-2, and
cyclin D2. mRNA levels were normalized by b-actin. Data were expressed as mean SE. P-values were calculated with Student’s t-test. Differences were considered signiﬁcant
at P< 0.01.
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presence of matrigel than in its absence. Concomitantly, XIAP and
Bcl-2 levels markedly decreased. In addition, in the presence of
matrigel pAKT levels potently lowered, while b1-integrin and pFAK
levels signiﬁcantly increased with pFAK and pAKT signiﬁcantly
accumulating in the nucleus. Most intriguingly, in cells engrafted
with matrigel hyperphosphorylated pRb levels became undetectable
whereas the total pRb levels remained unchanged.
Comparing mRNA extracted from FFPE tumors produced by
engraftment with and without matrigel, Real Time RT-PCR assay
(Fig. 6C) showed that beta-catenin, c-Myc, Bcl-2, and Cyclin D2
expression potently decreased in the presence of matrigel.
Overall, these results suggest that pAkt, b1-integrin, and pFAK
signaling pathways are crucial for 3AB-OS cells tumorigenicity.
However, when tumor cells reach a high density, matrigel might
provide the cues for both restraining cell proliferation and inducing
myoblast differentiation.
DISCUSSION
To obtain preclinical results with high predictive value for clinical
trials, it is crucial to have reliable in vivo tumor models on which
new compounds and novel drug combinations can be evaluated
[Ce´spedes et al., 2006; Troiani et al., 2008].
The CSC model represents nowadays an expanding ﬁeld in cancer
research that aims to identify the molecular mechanisms by which
CSCs arise and acquire their stem-like characteristics and to
establish how these cells can be selectively targeted and killed
[Giordano et al., 2007].
Many established models of anti-tumor chemotherapy are based
upon the successful propagation of established cell lines of human
origin, as subcutaneous xenografts in athymic nude mice. However,
although xenografts can provide valuable models for human
cancers, many tumors can be difﬁcult to establish [Sharkey and
Fogh, 1984; Troiani et al., 2008] thus, the identiﬁcation of factors
that facilitate the growth of xenografts is of great interest. One
possible way of improving such assay systems is the use of basement
membrane components, as the extracellular matrices underlying
epithelial cells (basement membranes) might inﬂuence cellular
behavior through a variety of regulatory factors.
Matrigel is a solubilized tissue basement membrane matrix,
extracted from the EHS mouse tumor, which resembles the complex
extracellular environment found in many tissues. A number of
articles have shown that matrigel can help to establish xenografts
from a variety of cell lines [Topley et al., 1993].
In this study, aimed at obtaining a suitable in vivo model of
human osteosarcoma CSCs, we have subcutaneously injected in
athymic mice both 3AB-OS osteosarcoma CSCs (which we
previously isolated from MG63 cells [Di Fiore et al., 2009], and
the parental MG63 human osteosarcoma cells, either in the absence
or in the presence of matrigel. We have shown that while MG63 cells
do not possess tumor-forming ability in vivo, 3AB-OS cells instead
were highly tumorigenic and matrigel greatly accelerated both
tumor engraftment and growth rate.
Pluripotency and immortality in CSCs depend on the expression
of a group of genes (stemness genes) which form a self-organized
core of transcription factors required for maintaining stem cell-like
features [Chen and Daley, 2008; Meng et al., 2012]. In particular,
four factors (Oct4, Sox2, Nanog, and Lin28) are sufﬁcient to
reprogram human somatic cells to pluripotent stem cells showing
the essential characteristics of embryonic stem (ES) cells [Yu et al.,
2007]. These induced pluripotent human stem cells express
telomerase activity, cell surface markers and genes that characterize
human ES cells, and maintain the developmental potential to
differentiate into advanced derivatives of all three primary germ
layers [Cox and Rizzino, 2010].
We have previously shown that 3AB-OS cells have a strong
stemness potential as they highly express a large panel of stemness-
related genes, such as CD133, Nanog, Oct3/4, SOX2, h-TERT,
HMGA2, Nucleostemin, ABCG2, Nestin, and Lin28B [Di Fiore et al.,
2009; Di Fiore et al., paper submitted]. Here, we have shown that
when 3AB-OS cells were engrafted in nude mice, they fully
preserved their stemness features. Indeed, during the ﬁrst weeks of
engraftment, both in the presence and absence of matrigel, the
stemness-related set of genes (including CD133, Nanog, SOX2, Oct3/
4, h-TERT, HMGA2, Nucleostemin, ABCG2, Nestin, and Lin28B,) was
TABLE V. Potential Signaling Pathways Involving in the Tumorigenicity of 3AB-OS Cancer Stem Cells
Akt/Wnt pathway
related markers
 Matrigel þ Matrigel  Matrigel þ Matrigel
5 weeks (positivity) 3 weeks (positivity) 7 weeks (positivity) 5 weeks (positivity)
% Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees % Mean S.D. Degrees
pRb (Ser 795) 70.2 4.1 þþ 72.7 2.6 þþþ 63.1 2.6 þþ —
pRb 71.8 3.7 þþþ 74.6 2.5 þþþ 72.4 2.5 þþþ 75.4 4.2 þþþ
cyclin-D2 83.6 5.3 þþþ 85.2 3.8 þþþ 68.6 3.8 þþ 57.9 4.5 þþ
c-MYC 72.4 3.3 þþþ 74.1 3.6 þþþ 57 3.6 þþ 39.4 3.3 þþ
GSK-3b — — — —
E-cadherin — — — —
APC — — — —
pAKT (Ser 473) 90.1 2.6 þþþ 96.6 1.7 þþþ 52.3 1.7 þþ 35.2 3.4 þþ
b1-integrin 59 3.5 þþ 61 4.3 þþ 55.4 4.3 þþ 78.1 3.3 þþþ
pFAK (Tyr 397) 74.3 2.8 þþþ 77 1.9 þþþ 65 3.8 þþ 93 4.4 þþþ
b-catenin 71,7 3.8 þþþ 69,7 5.8 þþ 61.7 1.6 þþ 30.4 2.3 þþ
Bcl-2 95.3 3.4 þþþ 96.1 2.5 þþþ 65.7 3.7 þþ 44.1 4.2 þþ
XIAP 97.5 1.6 þþþ 98.2 1.3 þþþ 75.7 1.6 þþþ 45.8 4.5 þþ
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highly expressed. However, over time, matrigel presence in
xenografts potently lowered the levels of these markers. Assessment
of the tumor growth rate (tumor weight and volume measurements)
and proliferation index (PCNA and Ki-67 analyses) showed that,
during the ﬁrst weeks of engraftment, both tumor growth and cell
proliferation increased, thereafter, over time, these indices signiﬁ-
cantly lowered, with the presence of matrigel greatly accelerating
these events. These ﬁndings suggested that matrigel, interacting
with the microenvironment, might regulate tumor cell behavior
providing the adequate cues for a gradual loss of stemness.
Genetic alterations and cytopathological heterogeneity charac-
terize osteosarcomas and contribute to the intractability of the
disease [Smida et al., 2010]. Osteosarcoma has been proposed to be a
differentiation-ﬂawed disease [Siclari and Qin, 2010]. In numerous
tumors during cancer progression a partial or complete loss of
E-cadherin has been described [Jeanes et al., 2008; Mohamet et al.,
2011]. E-cadherin controls the levels of free-cytosolic b-catenin and
loss of E-cadherin results in the disruption of cell–cell adhesion, in
increased cytosolic and nuclear b-catenin levels and in increased
cell proliferation. Loss of E-cadherin-mediated cell adhesion is one
of the key mechanisms involved in metastasis and in epithelial-
mesenchymal transition [Kalluri and Weinberg, 2009]. However,
b-catenin level is also regulated by the b-catenin destruction
complex (APC, Axin, GSK3b, and casein kinase), which modulates
Wnt pathway through the GSK-3b-APC complex [MacDonald et al.,
2009]. Alteration of this system leads to b-catenin stabilization
and nuclear accumulation and the consequent transcription of
genes (i.e., c-Myc and D cyclins) implicated in self-renewal [Ponce
et al., 2011].
At present, we do not know how CSCs originate in osteosarcomas.
However, the hypothesis that cancer arises from a tumorigenic
subpopulation of CSCs that, during the course of tumorigenesis,
accumulate multiple genetic alterations leading to an altered gene
expression pattern [Gisselsson, 2011], generates the need to analyze
CSCs for better understanding disease pathogenesis and for
developing speciﬁc targeted therapy. We have previously shown
[Di Fiore et al., 2009] that 3AB-OS cell cycle has an abbreviated
G1-S phase accompanied by a strong G2-M transition. In particular,
in 3AB-OS cells the pRb protein (which is known to inﬂuence the
timing of G1-S) is constitutively inactivated through hyperpho-
sphorylation and this is accompanied by high levels of nuclear
b-catenin and a potent increase in cyclin D1 (responsible for
mediating pRb phosphorylation) with an acceleration of the G1-S
phase transition. In addition, 3AB-OS cells express high levels of
cyclin B1 and cyclin-dependent kinases cdc-2, which promote G2-M
phase transition. Moreover, 3AB-OS cells express many anti-
apoptotic proteins (FlipL, Bcl-2, XIAP, IAP1, IAP2, and survivin).
Overall, our ﬁndings suggest that 3AB-OS cells are endowed with a
high proliferative capacity.
In this article, we have shown that engrafted tumor cells do not
express E-cadherin, APC, and GSK-3beta, thus lacking the crucial
regulators of soluble b-catenin levels. However, during the ﬁrst
weeks of engraftment they contain high levels of the phosphorylated
form of AKT, pAKT, which has been reported to be necessary for the
AKT-dependent up-regulation of b-catenin transcriptional activity
[Tian et al., 2004; Fang et al., 2007; Ponce et al., 2011]. Consistently,
engrafted tumor cells show high levels of nuclear b-catenin, c-Myc,
and cyclin D2, along with the hyperphosphorylated-inactive pRb
form, which conﬁrms the lack of brakes to restrain cell proliferation.
Similarly, the high levels of the antiapoptotic proteins, Bcl-2 and
XIAP, show that the strong proliferative potential of the 3AB-OS
cells was not counteracted by apoptosis.
Over time, signiﬁcant changes were observed in the tumor cell
composition of xenografts derived by 3AB-OS co-injection with
matrigel. Tumors showed the appearance of blood vessels and
muscle ﬁbers that in large number crossed the cancer mass.
Understanding the molecular mechanisms controlling cell fate
decisions in mammals is a major objective in CSC research. We have
recently shown (paper in preparation) that 3AB-OS cells, under
appropriate culture conditions, can be induced to differentiate
into derivatives of all three primary germ layers. Here, measuring
GFAP (ectodermal), vimentin (mesodermal), and AFP (endodermal)
expression, we have shown that engrafted tumor cells fully
preserved 3AB-OS multilineage commitment. In addition, a higher
expression level of these markers was found in the presence of
matrigel mixed cells or prolonging time of engrafment. However,
the more interesting aspect concerns mesodermal commitment, as
in the presence of matrigel engrafted 3AB-OS cells seemed to meet
the appropriate environmental cues for committing along the
mesenchymal lineage, with activation of myoblast differentiation.
Differentiation of muscle progenitors is a multistep process that
involves cell cycle withdrawal, expression of muscle-speciﬁc genes,
and formation of multinucleated myoﬁbers by cell fusion [Sun et al.,
2004]. Moreover, it requires speciﬁc, but poorly understood, cell
signals. Integrin b1 and FAK have been shown to be required for
myoblast differentiation, especially for myotube formation and it
has been shown that the integrin/FAK signaling pathway regulates
the expression of the promyogenic factors, including MyoD [Han
et al., 2011]. It is also known that myoblast differentiation requires
dephosphorylation of the retinoblastoma pRb protein and that
underphosphorylated pRb [Markiewicz et al., 2005] increases the
transcriptional ability of MyoD family of muscle gene regulatory
factors [Dick, 2007]. It has been proposed that a regulatory
checkpoint in the terminal cell cycle arrest of myoblasts during
differentiation involves the modulation of the cyclin D cdk-
dependent phosphorylation of pRb through the opposing effects of
cyclin D1 and MyoD [Kitzmann and Fernandez, 2001].
Here, we have shown that during the ﬁrst weeks of engraftment
tumor cells express high levels of b1-integrin along with
phosphorylated FAK. Thereafter, in time—when in the presence
of matrigel tumor cells appear to be enriched with blood vessels and
muscle ﬁbers—stemness, proliferative potential, and pAKT levels
potently decreased, while b1-integrin and pFAK still increased
with pFAK accumulating in the nuclei. Concomitantly, nuclear
b-catenin, c-Myc, and cyclin D2 markedly decreased and hyperpho-
sphorylated pRb forms became unmeasurable, whereas total pRb
levels did not change, thus suggesting a potent increase in
underphosphorylated pRb form. Our ﬁndings suggest that matrigel,
interacting with the subcutaneous microenvironment, might
regulate 3AB-OS cell behavior providing the adequate cues for
transducing either oncogenic or differentiation signals transmitted
by pAKT, integrin, and pFAK and supported by pRb protein.
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For several malignancies, tumor xenografts in mice have proven
to be reliable tools to predict drug response in vivo and the drug
industry has recognized the potential utility of tumorgrafts for
screening drug candidates. Our results provide for the ﬁrst time
a model of subcutaneous tumor engraftment with human osteo-
sarcoma CSCs. Our novel model seems to have the appropriate
characteristics to serve as a promising tool to investigate
osteosarcoma stem cell features and for appropriately targeting
CSCs by identifying links between the engrafted cells and their
microenvironment.
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